Previous Close | 7.27 |
1-Year Change | -66.34% |
6-Months Change | -48.8% |
3-Months Change | 10.15% |
Moving Avg (50d) | 8.125 |
Moving Avg (200d) | 13.5052 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 0.778B |
Beta (3-Years) | 1.96 |
Revenue Growth (ttm) | 2502.26% |
Net Profit Margin (ttm) | -68.15% |
Return On Assets (ttm) | -14.86% |
EPS (ttm) | -0.6 |
PE Ratio (ttm) | -12.12 |
Dividend Yield | % |
Asset Description: | bluebird bio, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2025-02-03 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
7.415 | 7.633 | 7.779 | 7.997 | 8.36 | 8.724 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |